Establishing a Large Tumor Organoid Biobank using a Well-Characterized/Annotated Patient-Derived Xenograft (PDX) Library to Enable Drug Discovery and Translational Research
Xiaoxi Xu, Limei Shang, Lili Wang, Chunmei Li, Yan Liu, Peng Han, Zhongman Sun, Yaping Qu, Likun Zhang, Bonnie Chen, Davy Ouyang, Yujun Huang, Henry Li
Patient-derived xenografts (PDX) and patient-derived organoids (PDO) are both predictive, cancer stem cell derived models for preclinical research. Deriving 3D in vitro organoids from large libraries of PDX rather than patient tissue allows the rapid generation of PDX-derived organoids (PDXO), as well as in vitro/in vivo matched models for predictive and translational drug development.
This poster details the generation of a panel of PDXO across a range of cancer types from our library of over 2,500 PDX models. The PDXO were generated using Hubrecht Organoid Technology (HUB) protocols originating from the Clevers lab.
Read this Poster to Discover:
- The establishment of over 100 PDXOs from more than 10 cancer types using HUB methods, with cellular/structural similarities maintained from PDX to 3D PDXO models
- How standard of care PDXO in vitro sensitivity data largely correlate to in vivo PDX treatment response
- How a library of matched in vitro PDXO/in vivo PDX models has high translational power, enables high throughput screening, and is likely to become an important tool for future oncology drug discovery and development